CA2538895A1 - Factor ixa specific antibodies displaying factor viiia like activity - Google Patents

Factor ixa specific antibodies displaying factor viiia like activity Download PDF

Info

Publication number
CA2538895A1
CA2538895A1 CA002538895A CA2538895A CA2538895A1 CA 2538895 A1 CA2538895 A1 CA 2538895A1 CA 002538895 A CA002538895 A CA 002538895A CA 2538895 A CA2538895 A CA 2538895A CA 2538895 A1 CA2538895 A1 CA 2538895A1
Authority
CA
Canada
Prior art keywords
antibody
factor
seq
nos
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002538895A
Other languages
English (en)
French (fr)
Inventor
Friedrich Scheiflinger
Randolf Kerschbaumer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34273861&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2538895(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2538895A1 publication Critical patent/CA2538895A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002538895A 2003-09-12 2004-09-07 Factor ixa specific antibodies displaying factor viiia like activity Abandoned CA2538895A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/661,366 US7297336B2 (en) 2003-09-12 2003-09-12 Factor IXa specific antibodies displaying factor VIIIa like activity
US10/661,366 2003-09-12
PCT/EP2004/009975 WO2005025615A2 (en) 2003-09-12 2004-09-07 FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY

Publications (1)

Publication Number Publication Date
CA2538895A1 true CA2538895A1 (en) 2005-03-24

Family

ID=34273861

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002538895A Abandoned CA2538895A1 (en) 2003-09-12 2004-09-07 Factor ixa specific antibodies displaying factor viiia like activity

Country Status (9)

Country Link
US (1) US7297336B2 (https=)
EP (1) EP1660536B1 (https=)
JP (1) JP4887148B2 (https=)
AT (1) ATE419277T1 (https=)
AU (1) AU2004271706B2 (https=)
CA (1) CA2538895A1 (https=)
DE (1) DE602004018788D1 (https=)
ES (1) ES2320665T3 (https=)
WO (1) WO2005025615A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
CA2603264C (en) * 2005-04-08 2017-03-21 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
EP1760092A1 (en) * 2005-08-26 2007-03-07 Applied Research Systems ARS Holding N.V. System for screening cells for high expression of a protein of interest
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
PH12016502073B1 (en) 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
CN104937423B (zh) * 2012-09-28 2017-05-24 中外制药株式会社 凝血反应的评价方法
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
AU2015229448B2 (en) 2014-03-11 2020-09-03 The Board Of Trustees Of The Leland Stanford Junior University Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
CN109563154B (zh) * 2016-05-16 2024-12-13 武田药品工业株式会社 抗帕多瓦因子ix抗体
KR102591955B1 (ko) 2016-07-29 2023-10-19 추가이 세이야쿠 가부시키가이샤 증강된 fviii 보인자 기능 대체 활성을 갖는 이중특이성 항체
RU2766233C2 (ru) 2016-09-06 2022-02-10 Чугаи Сейяку Кабусики Кайся Способы применения биспецифического антитела, которое распознает фактор свертывания ix и/или активированный фактор свертывания ix и фактор свертывания x и/или активированный фактор свертывания x
WO2018053597A1 (en) * 2016-09-23 2018-03-29 Csl Limited Coagulation factor binding proteins and uses thereof
US20230192896A1 (en) * 2016-11-23 2023-06-22 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
EP3577140A1 (en) 2017-02-01 2019-12-11 Novo Nordisk A/S Procoagulant antibodies
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
AR113142A1 (es) 2017-09-29 2020-01-29 Chugai Pharmaceutical Co Ltd Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
AU2018361430B2 (en) 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
JP6761142B1 (ja) 2018-08-01 2020-09-23 ノヴォ ノルディスク アー／エス 改良された血液凝固促進抗体
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
PL3723858T3 (pl) 2018-12-21 2022-03-07 Kymab Limited Przeciwciało dwuswoiste fixaxfx o wspólnym łańcuchu lekkim
CN115052898B (zh) 2020-01-30 2025-09-16 诺和诺德股份有限公司 双特异性因子viii模拟抗体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT368883B (de) 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2143125C (en) 1992-08-27 2008-09-23 Koenraad Mertens Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
DK128093D0 (da) 1993-11-12 1993-11-12 Novo Nordisk As Hidtil ukendte forbindelser
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
WO1999001476A1 (en) 1997-07-03 1999-01-14 Smithkline Beecham Corporation CRYSTAL STRUCTURES OF ANTI-FACTOR IX Fab FRAGMENTS AND METHODS OF USE FOR PEPTIDOMIMETIC DESIGN
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
PT1383785E (pt) * 2001-05-03 2011-06-28 Merck Patent Gmbh Anticorpo recombinante específico de tumores e utilização deste

Also Published As

Publication number Publication date
AU2004271706A1 (en) 2005-03-24
JP4887148B2 (ja) 2012-02-29
EP1660536A2 (en) 2006-05-31
US20050058640A1 (en) 2005-03-17
AU2004271706B2 (en) 2010-09-02
DE602004018788D1 (de) 2009-02-12
WO2005025615A2 (en) 2005-03-24
EP1660536B1 (en) 2008-12-31
JP2007504812A (ja) 2007-03-08
WO2005025615A3 (en) 2005-06-02
ES2320665T3 (es) 2009-05-27
ATE419277T1 (de) 2009-01-15
US7297336B2 (en) 2007-11-20

Similar Documents

Publication Publication Date Title
CA2538895A1 (en) Factor ixa specific antibodies displaying factor viiia like activity
JP7146871B2 (ja) 血漿カリクレイン結合タンパク質
EP1220923B1 (en) FACTOR IX/FACTOR IXa ACTIVATING ANTIBODIES
JP6900500B2 (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
CN102143979B (zh) 针对组织因子途径抑制剂(tfpi)的单克隆抗体
ES2765418T3 (es) Anticuerpos monoclonales optimizados contra el inhibidor de la ruta del factor tisular (TFPI)
JP2019507107A (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体及びその使用
CN105713092A (zh) 血浆前激肽释放酶结合蛋白
TW201522368A (zh) 抗組織因子路徑抑制劑之前藥抗體
WO2006117910A1 (ja) 抗血小板膜糖蛋白質ⅵモノクローナル抗体
JPH09502708A (ja) Ｉｌ４により伝達される疾患の治療に有用な組み換え型ｉｌ４抗体
BRPI0707848A2 (pt) mÉtodos para selecionar pelo menos uma molÉcula, para produzir uma composiÇço, para incrementar degradaÇço de proteÍna extracelular e / ou eliminaÇço de proteÍna em um indivÍduo, para inibir, pelo menos em parte, efeitos mediados por proteÍna mal-dobrada e e/ou estrutura b cruzada, para prevenÇço pelo menos parcial e/ou tratamento de uma doenÇa, de um distérbio e/ou de uma infecÇço, para remover, pelo parcialmente, proteÍnas mal-dobradas, estruturas b cruzadas e/ou proteÍnas, para determinar se uma proteÍna mal-dobrada, e/ou uma proteÍna e/ou peptÍdeo compreendendo uma estrutura b cruzada estÁ presente em uma soluÇço aquosa, para reduzir e/ou prevenir efeitos secundÁrios indesejados de uma composiÇço farmacÊutica e/ou incrementar a atividade especÍfica por grama de proteÍna, para interferir na coagulaÇço do sangue, para determinar a quantidade de proteÍnas mal-dobradas e/ou estruturas b cruzadas em uma composiÇço, para determinar uma diferenÇa no teor de estrutura b cruzada, para determinar a identidade de uma proteÍna mal-dobrada, de uma estrutura b cruzada ou de uma proteÍna, e para tratar um sujeito que sofre de, ou em risco de sofrer de, uma doenÇa, um distérbio e/ou uma infecÇço, coleÇço de molÉculas de igiv, composiÇço, uso de uma coleÇço de molÉculas igiv e/ou de uma composiÇço, kit diagnàstico, dispositivo de separaÇço, composto, e, uso de um composto
JP2002523081A (ja) ヒト抗−ＩＸ／ＩＸａ因子抗体
TW200407335A (en) Non-neutralizing antibody to inhibit the inactivation of activated protein C
US20140271661A1 (en) Monoclonal antibodies against antithrombin beta
WO2008050907A1 (fr) Anticorps dirigé contre rgd dans une séquence d'acides aminés d'une protéine de matrice extracellulaire et procédé de fabrication et utilisation de celui-ci
TWI673063B (zh) 抗蛋白ｃ抗體之出血性疾病的治療
BR112018069283B1 (pt) Anticorpos monoclonais contra o sítio ativo de fator xi e usos dos mesmos

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130107